Abstract:e20570 Background: For locally advanced unresectable NSCLC, studies of PD-1 inhibitor plus chemo as induction therapy and its roles on subsequent surgical resection are still limited. In this study, a consecutive series of unresectable stage III NSCLC patients were collected to investigate the surgical outcome and postoperative symptom changes in locally advanced patients who received adjuvant chemotherapy combined with immunotherapy. Methods: 92 locally advanced NSCLC patients received 2-4 cycles of chemotherapy combined with immunotherapy. Surgical rates, major pathologic remissions(MPR), pathologic complete remissions(PCR), postoperative complications, and immune-related adverse reactions(irAEs) were assesd. The follow-up of symptoms was performed during treatment and within 3 months postoperatively, and symptom changes were described based on patient-reported outcomes. Results: 26.09% of patients developed irAEs, the most common was skin toxicity, followed by thyroid dysfunction. 71.74% of patients underwent surgical resection. 63.64% (42/66) achieved MPR and PCR, of which 37.87% (25/66) were PCR. Most of these patients have clinical symptoms at the time of presentation, mainly cough (90%), and after treatment, cough is significantly reduced compared with before treatment. After treatment, the cough was significantly reduced compared with before treatment , nausea and vomiting , loss of appetite , dry mouth , and diarrhea were increased or aggravated. The most common symptoms on the first day after operation included pain (90%), shortness of breath (62.5%), fatigue (45%), cough (42.5%), and dry mouth (37.5%). On the third day after surgery, the incidence and severity of each symptom changed significantly, pain and dry mouth decreased significantly compared with before, cough, shortness of breath, and fatigue worsened and the incidence increased. Pain remains the most severe symptom in the early postoperative period, with the most severe on the first day after operation and then reduced, returning to preoperative levels 1.5 months after surgery. Cough was the main symptom at the time of presentation, which was significantly reduced after preoperative treatment, and the incidence and severity of postoperative cough increased significantly compared with preoperative treatment and returned to the preoperative level within 1 week after surgery. Dyspnea lasts long after surgery. Two weeks after surgery, shortness of breath (dyspnea) becomes the most obvious symptom. Conclusions: Preoperative chemotherapy combined with immunotherapy provides more opportunities for radical resection in locally advanced NSCLC patients. The most common postoperative symptoms are pain, dyspnea, cough, and fatigue; dyspnea is the symptom that affects patients the most and lasts the longest after surgery.

Dendritic Cells Immunotherapy Combined with Chemotherapy Inhibits Postoperative Recurrence and Metastasis in Stage IB of NSCLC after Radical Surgery

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer

Efficacy and Safety of Pembrolizumab Plus Chemotherapy and Sequential Surgical Resection in Initial Unresectable Stage IIIB NSCLC.

A Prospective Study of the Efficacy of a Combination of Autologous Dendritic Cells, Cytokine-Induced Killer Cells, and Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients

Impact of Dendritic Cells Combining with Cytokine-Induced Killer Cells Synergized Chemotherapy in Patients of Advanced Non-Small Cell Lung Cancer.

Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I–II non-small cell lung cancer after curative surgery

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.

Dendritic Cells Combining with Cytokine-Induced Killer Cells Synergize Chemotherapy in Patients with Late-Stage Non-Small Cell Lung Cancer

Effect of dendritic cell immunotherapy on distribution of dendritic cell subsets in non-small cell lung cancer

Surgical outcomes and patient-reported outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy.

Survival Study of Neoadjuvant Versus Adjuvant Chemotherapy with Docetaxel Combined Carboplatin in Resectable Stage IB to IIIA Non-Small Lung Cancer.

Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study

Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Adjuvant Chemotherapy May Improve Outcome of Patients with Non-Small-cell Lung Cancer with Metastasis of Intrapulmonary Lymph Nodes after Systematic Dissection of N1 Nodes

Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective

OA09.03 Randomized Controlled Study Comparing Adjuvant versus Neo-Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study

Prognostic Factors Affecting Long-Term Outcomes in Patients with Resected Stage Iiia Pn2 Non-Small-Cell Lung Cancer: 5-Year Follow-Up of A Phase Ii Study

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)